A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

D. Godelaine; Javier Carrasco; F. Brasseur; Bart Neyns; Kris Thielemans; Thierry Boon; Aline Van Pel

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

D. Godelaine, Javier Carrasco, F. Brasseur, Bart Neyns, Kris Thielemans, Thierry Boon, Aline Van Pel

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

Original language	English
Pages (from-to)	753-759
Number of pages	7
Journal	Cancer Immunol Immunother
Volume	56
Issue number	June
Publication status	Published - 2007

Keywords

antigenic peptide
cancer immunotherapy
cytolic T lymphocytes
MAGE
melanoma

Access to Document

http://apps.isiknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=20&SID=R1@5Kol@FnpLohpK2Ak&page=1&doc=1&colname=WOS

Handle.net

Persistent link

Cite this

Godelaine, D., Carrasco, J., Brasseur, F., Neyns, B., Thielemans, K., Boon, T., & Van Pel, A. (2007). A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother, 56(June), 753-759. http://apps.isiknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=20&SID=R1@5Kol@FnpLohpK2Ak&page=1&doc=1&colname=WOS

@article{6afa2ce0b36f4c6387e6380f47874c42,

title = "A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44",

abstract = "A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.",

keywords = "antigenic peptide, cancer immunotherapy, cytolic T lymphocytes, MAGE, melanoma",

author = "D. Godelaine and Javier Carrasco and F. Brasseur and Bart Neyns and Kris Thielemans and Thierry Boon and {Van Pel}, Aline",

year = "2007",

language = "English",

volume = "56",

pages = "753--759",

journal = "Cancer Immunol Immunother",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "June",

}

Godelaine, D, Carrasco, J, Brasseur, F, Neyns, B , Thielemans, K, Boon, T & Van Pel, A 2007, 'A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44', Cancer Immunol Immunother, vol. 56, no. June, pp. 753-759. <http://apps.isiknowledge.com.ezproxy.vub.ac.be:2048/full_record.do?product=UA&search_mode=GeneralSearch&qid=20&SID=R1@5Kol@FnpLohpK2Ak&page=1&doc=1&colname=WOS>

TY - JOUR

T1 - A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

AU - Godelaine, D.

AU - Carrasco, Javier

AU - Brasseur, F.

AU - Neyns, Bart

AU - Thielemans, Kris

AU - Boon, Thierry

AU - Van Pel, Aline

PY - 2007

Y1 - 2007

N2 - A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

AB - A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

KW - antigenic peptide

KW - cancer immunotherapy

KW - cytolic T lymphocytes

KW - MAGE

KW - melanoma

M3 - Article

SN - 0340-7004

VL - 56

SP - 753

EP - 759

JO - Cancer Immunol Immunother

JF - Cancer Immunol Immunother

IS - June

ER -

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this